Biotech company GeneThera said last week that it will expand its efforts to commercialize a diagnostic platform for Johne's disease, an uncurable bacterial disease affecting the intestinal tract of livestock, by inking licensing agreements with a pair of Italian universities.

Specifically, GeneThera said that it is currently negotiating formal licensing agreements with the Universita di Roma "Tor Vegata" and Universita Cattolica del Sacro Cuore, which have jointly developed a potential liposome-based therapeutic for the disease.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Sometimes genetic tests give inconclusive results and provide little reassurance to patients, the Associated Press reports.

Vox wonders whether gene-editing crops will be viewed similarly as genetically modified organisms of if people will give them a try.

In Science this week: research regulation and reporting requirement reform, and more.

With H3Africa, Charles Rotimi has been working to bolster the representation of African participants and African researchers in genomics, Newsweek reports.